ArticleOne health (Amsterdam, Netherlands)2026
A critical analysis of the quadripartite one health joint plan of action.
Article in One health (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Quadripartite One Health Joint Plan of Action (2022-2026), now extended to 2029, represents an important effort to consolidate One Health as a global policy framework. This article critically examines the Plan's achievements and structural constraints. Key strengths include the consolidation of political commitment, the formalisation of institutional alignment at global level, and the prioritisation of prevention, preparedness, and integrated surveillance. Environmental governance was formally included, recognising ecosystem degradation and biodiversity loss as upstream drivers of risk. However, although later guidance added an operational layer, the Plan remains predominantly normative, its financing guidance says more about mobilising investment than about sustaining recurrent functions, and participatory mechanisms remain predominantly consultative. Its framing continues to privilege health security over long-term socioecological determinants and routine practice. The article proposes priorities for the structured review and next phase: clearer implementation pathways with comparable reporting, coordinated investment, participatory governance, and One Health embedded in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.